Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Subtype-selective nicotinic acetylcholine receptor agonists enhance the responsiveness to citalopram and reboxetine in the mouse forced swim test.

Andreasen JT, Nielsen EØ, Christensen JK, Olsen GM, Peters D, Mirza NR, Redrobe JP.

J Psychopharmacol. 2011 Oct;25(10):1347-56. doi: 10.1177/0269881110364271. Epub 2010 Apr 1.

PMID:
20360159
2.

Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests.

Andreasen JT, Redrobe JP.

Behav Brain Res. 2009 Jan 30;197(1):150-6. doi: 10.1016/j.bbr.2008.08.016. Epub 2008 Aug 22.

PMID:
18786574
3.
4.

Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests.

Andreasen JT, Olsen GM, Wiborg O, Redrobe JP.

J Psychopharmacol. 2009 Sep;23(7):797-804. doi: 10.1177/0269881108091587. Epub 2008 Jun 26.

PMID:
18583432
5.

Chronic oral nicotine increases brain [3H]epibatidine binding and responsiveness to antidepressant drugs, but not nicotine, in the mouse forced swim test.

Andreasen JT, Nielsen EO, Redrobe JP.

Psychopharmacology (Berl). 2009 Aug;205(3):517-28. doi: 10.1007/s00213-009-1560-1. Epub 2009 May 12.

PMID:
19452140
6.

Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study.

Marcus MM, Björkholm C, Malmerfelt A, Möller A, Påhlsson N, Konradsson-Geuken Å, Feltmann K, Jardemark K, Schilström B, Svensson TH.

Eur Neuropsychopharmacol. 2016 Sep;26(9):1401-1411. doi: 10.1016/j.euroneuro.2016.07.004. Epub 2016 Jul 26.

PMID:
27474687
7.

Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats.

Zaniewska M, McCreary AC, Przegaliński E, Filip M.

Eur J Pharmacol. 2006 Jul 1;540(1-3):96-106. Epub 2006 May 3.

PMID:
16730696
8.

Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380.

Caldarone BJ, Wang D, Paterson NE, Manzano M, Fedolak A, Cavino K, Kwan M, Hanania T, Chellappan SK, Kozikowski AP, Olivier B, Picciotto MR, Ghavami A.

Psychopharmacology (Berl). 2011 Sep;217(2):199-210. doi: 10.1007/s00213-011-2271-y. Epub 2011 Apr 13.

9.

Additive subthreshold dose effects of cannabinoid CB(1) receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests.

Takahashi E, Katayama M, Niimi K, Itakura C.

Eur J Pharmacol. 2008 Jul 28;589(1-3):149-56. doi: 10.1016/j.ejphar.2008.05.020. Epub 2008 May 23.

PMID:
18571641
11.

Activation of α7 nicotinic acetylcholine receptors ameliorates indomethacin-induced small intestinal ulceration in mice.

Kawahara R, Yasuda M, Hashimura H, Amagase K, Kato S, Takeuchi K.

Eur J Pharmacol. 2011 Jan 10;650(1):411-7. doi: 10.1016/j.ejphar.2010.10.031. Epub 2010 Oct 20.

PMID:
20969854
12.

Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect.

Rollema H, Guanowsky V, Mineur YS, Shrikhande A, Coe JW, Seymour PA, Picciotto MR.

Eur J Pharmacol. 2009 Mar 1;605(1-3):114-6. doi: 10.1016/j.ejphar.2009.01.002. Epub 2009 Jan 10.

13.

The antidepressant-like action of metabotropic glutamate 7 receptor agonist N,N'-bis(diphenylmethyl)-1,2-ethanediamine (AMN082) is serotonin-dependent.

Pałucha-Poniewiera A, Brański P, Lenda T, Pilc A.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):1066-74. doi: 10.1124/jpet.110.169730. Epub 2010 Jun 18.

14.

5-HT(1A)-receptor over-expressing mice: genotype and sex dependent responses to antidepressants in the forced swim-test.

Günther L, Rothe J, Rex A, Voigt JP, Millan MJ, Fink H, Bert B.

Neuropharmacology. 2011 Sep;61(3):433-41. doi: 10.1016/j.neuropharm.2011.03.004. Epub 2011 Mar 17.

15.

The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior.

Sarkisyan G, Roberts AJ, Hedlund PB.

Behav Brain Res. 2010 May 1;209(1):99-108. doi: 10.1016/j.bbr.2010.01.022. Epub 2010 Jan 25.

16.

New quinoline derivatives as nicotinic receptor modulators.

Manetti D, Bellucci C, Dei S, Teodori E, Varani K, Spirova E, Kudryavtsev D, Shelukhina I, Tsetlin V, Romanelli MN.

Eur J Med Chem. 2016 Mar 3;110:246-58. doi: 10.1016/j.ejmech.2016.01.025. Epub 2016 Jan 19.

PMID:
26840365
17.

α4β2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like properties.

Mineur YS, Einstein EB, Seymour PA, Coe JW, O'neill BT, Rollema H, Picciotto MR.

Behav Pharmacol. 2011 Aug;22(4):291-9. doi: 10.1097/FBP.0b013e328347546d.

18.

Reboxetine attenuates forced swim test-induced behavioural and neurochemical alterations in the rat.

Connor TJ, Kelliher P, Harkin A, Kelly JP, Leonard BE.

Eur J Pharmacol. 1999 Aug 27;379(2-3):125-33.

PMID:
10497898
19.

Discovery of isoxazole analogues of sazetidine-A as selective α4β2-nicotinic acetylcholine receptor partial agonists for the treatment of depression.

Liu J, Yu LF, Eaton JB, Caldarone B, Cavino K, Ruiz C, Terry M, Fedolak A, Wang D, Ghavami A, Lowe DA, Brunner D, Lukas RJ, Kozikowski AP.

J Med Chem. 2011 Oct 27;54(20):7280-8. doi: 10.1021/jm200855b. Epub 2011 Sep 30.

20.

Cytisine-based nicotinic partial agonists as novel antidepressant compounds.

Mineur YS, Eibl C, Young G, Kochevar C, Papke RL, Gündisch D, Picciotto MR.

J Pharmacol Exp Ther. 2009 Apr;329(1):377-86. doi: 10.1124/jpet.108.149609. Epub 2009 Jan 22.

Supplemental Content

Support Center